Cas:456-63-3 1,1,2,2-tetrafluoroethoxycyclohexane manufacturer & supplier

Chemical Name:1,1,2,2-tetrafluoroethoxycyclohexane

CAS.NO:456-63-3

Synonyms:B-380;cyclohexyl-(1,1,2,2-tetrafluoro-ethyl)-ether;Cyclohexyl-(1,1,2,2-tetrafluor-aethyl)-aether;(1.1.2.2-Tetrafluor-aethoxy)-cyclohexan;Ether,cyclohexyl 1,1,2,2-tetrafluoroethyl;(1,1,2,2-Tetrafluoroethoxy)cyclohexane;1.1.2.2-Tetrafluor-1-cyclohexyloxy-aethan

Molecular Formula:C₈H₁₂F₄O

Molecular Weight:200.17400

HS Code:2909209000

Physical and Chemical Properties:

Melting point:N/A

Boiling point:142ºC

Density:1.16

Index of Refraction:1.3725

PSA:9.23000

Exact Mass:200.08200

LogP:3.19360

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like B-380 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1.1.2.2-Tetrafluor-1-cyclohexyloxy-aethan physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(1.1.2.2-Tetrafluor-aethoxy)-cyclohexan Use and application,(1.1.2.2-Tetrafluor-aethoxy)-cyclohexan technical grade,usp/ep/jp grade.

Related News: The Breakthrough Designation for the iLet Bionic Pancreas System contemplates configurations with most insulin analogs approved for pumping as well as dasiglucagon, Zealand Pharma��s stable pumpable glucagon analog, which has a unique stability profile in a ready-to-use aqueous solution. 1,1,2,2-tetrafluoroethoxycyclohexane manufacturer At present, Teva can produce more than 300 generic drugs, and the API department has approximately 650 authorized patents and patent applications worldwide. It is also the generic drug company with the most challenges in patenting ParagraphIV in the world. 1,1,2,2-tetrafluoroethoxycyclohexane supplier At present, there are more than 8,000 domestic API manufacturers, but they mainly produce bulk APIs with low technical content. 1,1,2,2-tetrafluoroethoxycyclohexane vendor At present, Teva can produce more than 300 generic drugs, and the API department has approximately 650 authorized patents and patent applications worldwide. It is also the generic drug company with the most challenges in patenting ParagraphIV in the world. 1,1,2,2-tetrafluoroethoxycyclohexane factory Retrogenix��s proprietary cell microarray technology provides a fast, accurate and effective solution for determining the primary target and secondary target (off-target) activities of antibodies, proteins, cell therapies, small molecules and viruses.